Form 4 for SGMT Sagimet Biosciences Inc.
Accepted 2024-03-28 00:00:00 ET · period of report 2024-03-26 · accession 0001104659-24-040517 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-28 | 2024-03-26 | SGMT | Happel David | Pres, CEO, Dir | P - Purchase | $5.27 | +12.1K | 639.2K | +2% | +$63.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Series A Common Stock | 2024-03-26 | P | A | 12,100 | $5.27 | 639,200 | D | — | — | (F1) Reflects the weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.24 per share to $5.2999 per share. The Reporting Person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each price. |